The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,114.00
Bid: 12,110.00
Ask: 12,114.00
Change: -42.00 (-0.35%)
Spread: 4.00 (0.033%)
Open: 12,092.00
High: 12,138.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

1 Dec 2021 15:00

RNS Number : 2427U
AstraZeneca PLC
01 December 2021
 

1 December 2021 15:00 GMT

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

 

Date: 1 December 2021

 

Name of applicant:

ASTRAZENECA PLC

Name of scheme:

ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME

Period of return:

From:

1 JUNE 2021

To:

30 NOVEMBER 2021

Balance of unallotted securities under scheme(s) from previous return:

5,252,778

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

65,397

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

5,187,381

 

Name of contact:

Hannah Tattersall

Telephone number of contact:

+44 (0)746 498 2582

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRFSLFEFEFSEEE
Date   Source Headline
28th Mar 20227:00 amRNSEvusheld approved in the EU for COVID-19
25th Mar 20223:30 pmRNSDirector/PDMR Shareholding
24th Mar 20226:00 pmRNSEvusheld Positive EU CHMP Opinion
24th Mar 20227:00 amRNSUpdate on CALLA Phase III trial for Imfinzi
23rd Mar 202211:00 amRNSNotice of AGM
17th Mar 20227:00 amRNSSettlement of patent litigation for Ultomiris
14th Mar 20227:05 amRNSLynparza approved in US for early breast cancer
14th Mar 20227:00 amRNSUpdate on US review of Fasenra in nasal polyps
9th Mar 20223:30 pmRNSDirector/PDMR Shareholding
7th Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20227:00 amRNSAstraZeneca and Neurimmune close deal for NI006
23rd Feb 20227:00 amRNSFiling of Form 20-F with SEC
22nd Feb 202211:00 amRNSChair succession planning update and Annual Report
21st Feb 20227:00 amRNSEnhertu improves PFS and OS in HER2-low BC
16th Feb 20227:00 amRNSSaphnelo approved in EU for SLE
15th Feb 20227:00 amRNSLynparza combo delays progression risk in prostate
11th Feb 20223:30 pmRNSDirector/PDMR Shareholding
10th Feb 20227:00 amRNSAZN: Full year and Q4 2021 results
1st Feb 20223:00 pmRNSTotal Voting Rights
19th Jan 20227:05 amRNSImfinzi improves survival in biliary tract cancer
19th Jan 20227:00 amRNSImfinzi combo shows unprecedented survival in HCC
17th Jan 20227:00 amRNSEnhertu granted Priority Review for breast cancer
7th Jan 20227:00 amRNSAstraZeneca and Neurimmune sign deal for NI006
5th Jan 20227:00 amRNSTransfer of rights to Eklira, Duaklir completed
4th Jan 20223:00 pmRNSTotal Voting Rights
29th Dec 20217:00 amRNSAstraZeneca and Ionis close eplontersen deal
21st Dec 20217:00 amRNSUltomiris accepted for FDA Priority Review for gMG
20th Dec 20217:05 amRNSTezspire approved in the US for severe asthma
20th Dec 20217:00 amRNSSaphnelo recommended for EU approval for SLE
15th Dec 20213:00 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSEvusheld US FDA EUA
7th Dec 20217:00 amRNSAstraZeneca, Ionis to collaborate on eplontersen
1st Dec 20213:00 pmRNSBlock listing Interim Review
1st Dec 20213:00 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSLynparza granted FDA Priority Review for OlympiA
15th Nov 20214:00 pmRNSDirector/PDMR Shareholding
12th Nov 20217:00 amRNSAZN: Year to date and Q3 2021 results
1st Nov 20213:00 pmRNSTotal Voting Rights
1st Nov 20217:00 amRNSAstraZeneca to transfer rights to Eklira, Duaklir
25th Oct 20217:00 amRNSImfinzi improved survival in biliary tract cancer
18th Oct 20217:00 amRNSAZ recommends ADS holders reject mini-tender offer
15th Oct 20217:00 amRNSImfinzi & tremelimumab improved OS in liver cancer
11th Oct 20217:00 amRNSAZD7442 PhIII trial positive in COVID outpatients
4th Oct 20217:00 amRNSEnhertu granted BTD for breast cancer
1st Oct 20213:00 pmRNSTotal Voting Rights
30th Sep 20214:00 pmRNSDirector/PDMR Shareholding
29th Sep 20217:00 amRNSAstraZeneca to fully acquire Caelum Biosciences
28th Sep 20217:00 amRNSSaphnelo approved in Japan for SLE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.